12 November 2019 | News
For Biosyngen biopharmaceutical technology transfer platform and to incubate companies
Stone Capital and Biosyngen have partnered to establish a Biopharmaceutical Investment Fund in Singapore, the signing ceremony was held in Ascendas One Hub of Sino-Singapore Guangzhou Knowledge City. The key investment targets of the biopharmaceutical fund of $50 million raised is for Biosyngen biopharmaceutical technology transfer platform and to incubate companies.
Biosyngen has been an angel investment platform for biopharmaceutical projects, who has formed projects with selected early stage technologies after stringent screening process. This fund allows Biosyngen to take advantage of Singapore pool of talent, technology, regulations, government support and other industrial resources, in particular cell therapy technologies, Biosyngen provides high-efficient incubation support and clinical transformation of the projects. The Company is also taking advantage of the Chinese government's policy support, environment and the rich clinical trial resources in China. When the projects reach certain level of maturity, they will be further developed and commercialised in China and ASEAN, thereby meeting the needs of both markets.
Wang Liqun, Chairman of Stone Capital and Director of Biosyngen; Dr. Victor Li Lietao, Founder and CEO of Biosyngen; and Wang Shuli, Chairman of Biosyngen attended the event to witness a milestone in the progress of the company. As a well-known successful investor, Wang expressed his appreciation for Biosyngen on the competency of project transformation over the past three years. He also generously shared his management experience and made suggestions to Dr. Li. Dr. Li expressed his sincere gratitude to Wang for coming onboard Biosyngen as a Director as this will enhance the function of Biosygnen biopharmaceutical technology transfer platform which will accelerate the business development of Biosyngen.
Photo caption- Shen Feiyu, Director of Biosyngen (seated, left); Dr. Victor Li Lietao, Founder, Director and CEO of Biosyngen (seated, middle); Mr. Wang Liqun, Chairman of Stone Capital and Director of Biosyngen (seated, right); Mr. Frank Wang, Chairman of Biosyngen (standing, 11th from left); Mrs. Michelle Chen, Director and Vice President of Biosyngen (standing, 7th from right)